Analgesic potential of PF-06372865, an a 2/ a 3/ a 5 subtype-selective GABA A partial agonist, in humans

Background: This study investigated the analgesic effects of two doses (15 and 65 mg) of PF-06372865, a novel a 2/ a 3/ a 5 gamma-aminobutyric acid A (GABA A ) subunit selective partial positive allosteric modulator (PAM), compared with placebo and pregabalin (300 mg) as a positive control. Methods: We performed a randomised placebo-controlled crossover study (NCT02238717) in 20 healthy subjects, using a battery of pain tasks (electrical, pressure, heat, cold and inflammatory pain, including a paradigm of conditioned pain modulation). Pharmacodynamic measurements were performed at baseline and up to 10h after dose. Results: A dose of 15 mg PF-06372865 increased pain tolerance thresholds (PTTs) for pressure pain at a ratio of 1.11 (90% confidence interval [CI]: 1.02, 1.22) compared with placebo. A dose of 65 mg PF-06372865 led to an increase in PTT for the cold pressor at a ratio of 1.17 (90% CI: 1.03, 1.32), and pressure pain task: 1.11 (90% CI: 1.01, 1.21). Pregabalin showed an increase in PTT for pressure pain at a ratio of 1.15 (95% CI: 1.06, 1.26) and cold pressor task: 1.31 (90% CI: 1.16, 1.48). Conclusion: We conclude that PF-06372865 has analgesic potential at doses that do not induce significant sedation or other intolerable adverse events limiting its clinical use. In addition, the present study established the potential role for this battery of pain tasks as a tool in the development of analgesics with a novel mechanism of action, for the treatment of various pain states including neuropathic pain and to establish proof-of-concept.

[1]  M. Kam,et al.  Effect profile of paracetamol, Δ9‐THC and promethazine using an evoked pain test battery in healthy subjects , 2018, European journal of pain.

[2]  Donal N. Gorman,et al.  Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF‐06372865 , 2018, British journal of pharmacology.

[3]  Donal N. Gorman,et al.  Demonstration of an anti‐hyperalgesic effect of a novel pan‐Trk inhibitor PF‐06273340 in a battery of human evoked pain models , 2018, British journal of clinical pharmacology.

[4]  Gonzalo Yevenes,et al.  Glycine receptors and glycine transporters: targets for novel analgesics? , 2017, Cellular and Molecular Life Sciences.

[5]  A. Rapkin,et al.  Experimental and procedural pain responses in primary dysmenorrhea: a systematic review , 2017, Journal of pain research.

[6]  L. Puljak,et al.  Interventions for Neuropathic Pain: An Overview of Systematic Reviews , 2017, Anesthesia and analgesia.

[7]  R. Chou,et al.  Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline , 2017, Annals of Internal Medicine.

[8]  A. Dahan,et al.  Pharmacokinetics and pharmacodynamics of intrathecally administered Xen2174, a synthetic conopeptide with norepinephrine reuptake inhibitor and analgesic properties , 2017, British journal of clinical pharmacology.

[9]  M. Kam,et al.  No evidence of potentiation of buprenorphine by milnacipran in healthy subjects using a nociceptive test battery , 2017, European journal of pain.

[10]  Kevin T. Beier,et al.  A Brainstem-Spinal Cord Inhibitory Circuit for Mechanical Pain Modulation by GABA and Enkephalins , 2017, Neuron.

[11]  M. Johantgen,et al.  Racial and ethnic differences in experimental pain sensitivity: systematic review and meta-analysis , 2017, Pain.

[12]  G. Groeneveld,et al.  A literature review on the pharmacological sensitivity of human evoked hyperalgesia pain models. , 2016, British journal of clinical pharmacology.

[13]  Jian Dong,et al.  The effect of pregabalin on acute postoperative pain in patients undergoing total knee arthroplasty: A meta-analysis. , 2016, International journal of surgery.

[14]  Y. Daali,et al.  The clobazam metabolite N-desmethyl clobazam is an α2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia , 2016, Neuropharmacology.

[15]  B. Ilfeld,et al.  An Evidence-Based Review of the Efficacy of Perioperative Analgesic Techniques for Breast Cancer-Related Surgery , 2016, Pain medicine.

[16]  G. Groeneveld,et al.  Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery , 2016, Journal of visualized experiments : JoVE.

[17]  P. Muglia,et al.  NS11821, a partial subtype-selective GABAA agonist, elicits selective effects on the central nervous system in randomized controlled trial with healthy subjects , 2016, Journal of psychopharmacology.

[18]  N. Calcutt,et al.  The &agr;5 subunit containing GABAA receptors contribute to chronic pain , 2016, Pain.

[19]  J. McDougall,et al.  Preclinical Assessment of Inflammatory Pain , 2016, CNS neuroscience & therapeutics.

[20]  D. Agrawal,et al.  Therapeutic Basis of Clinical Pain Modulation , 2015, Clinical and translational science.

[21]  S. McMahon,et al.  Ultraviolet Radiation on the Skin: A Painful Experience? , 2015, CNS neuroscience & therapeutics.

[22]  William T. Ralvenius,et al.  Analgesia and unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABAA receptor subtype , 2015, Nature Communications.

[23]  Y. Daali,et al.  GABAergic modulation in central sensitization in humans: a randomized placebo-controlled pharmacokinetic–pharmacodynamic study comparing clobazam with clonazepam in healthy volunteers , 2015, Pain.

[24]  Blair H. Smith,et al.  Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis , 2015, The Lancet Neurology.

[25]  C. Vaughan,et al.  Descending modulation of pain: the GABA disinhibition hypothesis of analgesia , 2014, Current Opinion in Neurobiology.

[26]  Nirmal Singh,et al.  Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms , 2014, Current neuropharmacology.

[27]  S. McMahon,et al.  Synthesis of Lipid Mediators during UVB-Induced Inflammatory Hyperalgesia in Rats and Mice , 2013, PloS one.

[28]  Gonzalo Yevenes,et al.  Antihyperalgesia by α2-GABAA Receptors Occurs Via a Genuine Spinal Action and Does Not Involve Supraspinal Sites , 2013, Neuropsychopharmacology.

[29]  R. Fillingim,et al.  Sex differences in pain: a brief review of clinical and experimental findings. , 2013, British journal of anaesthesia.

[30]  Rao P. Gullapalli,et al.  The role of circulating sex hormones in menstrual cycle–dependent modulation of pain-related brain activation , 2013, PAIN.

[31]  L. Arendt-Nielsen,et al.  Evaluation of Anti-Hyperalgesic and Analgesic Effects of Two Benzodiazepines in Human Experimental Pain: A Randomized Placebo-Controlled Study , 2013, PloS one.

[32]  J. Seibyl,et al.  Sex‐specific differences in GABAA‐benzodiazepine receptor availability: relationship with sensitivity to pain and tobacco smoking craving , 2013, Addiction biology.

[33]  J. Fritschy,et al.  Selective distribution of GABAA receptor subtypes in mouse spinal dorsal horn neurons and primary afferents , 2012, The Journal of comparative neurology.

[34]  E. Meloni,et al.  Benzodiazepine-induced anxiolysis and reduction of conditioned fear are mediated by distinct GABAA receptor subtypes in mice , 2012, Neuropharmacology.

[35]  F. Knoflach,et al.  Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes , 2011, Nature Reviews Drug Discovery.

[36]  Puneet Khanna,et al.  Pregabalin in acute and chronic pain , 2011, Journal of anaesthesiology, clinical pharmacology.

[37]  C. Edwards,et al.  Ethnic differences in cardiovascular-somatosensory interactions and in the central processing of noxious stimuli. , 2011, Psychophysiology.

[38]  Y. Daali,et al.  HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain , 2011, Neuropharmacology.

[39]  Sandra M. Sanabria-Bohórquez,et al.  Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist , 2011, Journal of psychopharmacology.

[40]  J. Verster,et al.  Effect of hypnotic drugs on body balance and standing steadiness. , 2010, Sleep medicine reviews.

[41]  J. Davidson,et al.  Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs. , 2010, Primary care companion to the Journal of clinical psychiatry.

[42]  P. Wiffen,et al.  Pregabalin for acute and chronic pain in adults. , 2009, The Cochrane database of systematic reviews.

[43]  Robert R. Edwards,et al.  Sex-based differences in pain perception and treatment. , 2009, Pain medicine.

[44]  H. Zeilhofer,et al.  Genuine Antihyperalgesia by Systemic Diazepam Revealed by Experiments in Gaba a Receptor Point-mutated Mice , 2008 .

[45]  E. Nielsen,et al.  Comparison of the Novel Subtype-Selective GABAA Receptor-Positive Allosteric Modulator NS11394 [3′-[5-(1-Hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with Diazepam, Zolpidem, Bretazenil, and Gaboxadol in Rat Models of Inflammatory and Neuropathic Pain , 2008, Journal of Pharmacology and Experimental Therapeutics.

[46]  Kay Brune,et al.  Reversal of pathological pain through specific spinal GABAA receptor subtypes , 2008, Nature.

[47]  G. Dawson,et al.  L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for α5-containing GABAA receptors , 2006, Neuropharmacology.

[48]  M. Kunz,et al.  GABAergic modulation of diffuse noxious inhibitory controls (DNIC): a test by use of lorazepam , 2006, Experimental Brain Research.

[49]  Loren J. Martin,et al.  α5GABAA Receptors Mediate the Amnestic But Not Sedative-Hypnotic Effects of the General Anesthetic Etomidate , 2006, The Journal of Neuroscience.

[50]  L. Jasmin,et al.  GABA puts a stop to pain. , 2004, Current drug targets. CNS and neurological disorders.

[51]  R. Mckernan,et al.  Which GABAA-receptor subtypes really occur in the brain? , 1996, Trends in Neurosciences.

[52]  G. Kobal,et al.  Psychophysiology of experimentally induced pain. , 1993, Physiological reviews.

[53]  James N. Campbell,et al.  Peripheral and central mechanisms of cutaneous hyperalgesia , 1992, Progress in Neurobiology.

[54]  J. Vane,et al.  Further experiments to establish that the analgesic action of aspirin-like drugs depends on the inhibition of prostaglandin biosynthesis. , 1973, British journal of pharmacology.

[55]  P. Wall,et al.  Pain mechanisms: a new theory. , 1965, Science.

[56]  L. Arendt-Nielsen,et al.  Mutations affecting glycinergic neurotransmission in hyperekplexia increase pain sensitivity , 2018, Brain : a journal of neurology.

[57]  Michael G Kenward,et al.  The use of baseline covariates in crossover studies. , 2010, Biostatistics.

[58]  Z. Luo,et al.  Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[59]  K. Vogt,et al.  Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[60]  D. Sirinathsinghji,et al.  Expression of GABA(A) receptor alpha5 subunit-like immunoreactivity in human hippocampus. , 2000, Brain research. Molecular brain research.

[61]  W. Catterall.  Structure and regulation of voltage-gated Ca2+ channels. , 2000, Annual review of cell and developmental biology.

[62]  J. Jester,et al.  A role for NF-kappaB-dependent gene transactivation in sunburn. , 2000, The Journal of clinical investigation.

[63]  J. Benson,et al.  Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. , 1999, Nature.

[64]  D. R. Curtis,et al.  Amino acid transmitters in the mammalian central nervous system. , 1974, Ergebnisse der Physiologie, biologischen Chemie und experimentellen Pharmakologie.